• December 1995

    Our beginnings

    Haixi China founded in Fujian, China.

  • June 2004

    Certification obtained

    GMP Certification issued by the SFDA was obtained.

  • October 2009

    New production facilities

    A new factory and production facility was obtained, along with the relevant building usage approvals issued by the Chinese government.

  • May 2011

    Business growth

    As part of the first phase of Haixi China's business expansion plans, a new factory and production facility was constructed.

  • November 2012

    SFDA approvals

    The new factory obtained pharmaceutical medicinal production and manufacturing approvals issued by the SFDA.

  • June 2013

    Production facilities expand

    Haixi China received government approvals from the Yong'an City Planning Bureau for its plan to expand the new factory by 70,000 square metres.

  • November 2013

    GMP Certifications

    The new factory obtained GMP Certifications for its production lines for oral liquid, tablet and capsule medicinal products.

  • May 2015

    Second phase completed

    Haixi China invested RMB 80,000,000 into increasing the production capacity of its production lines for oral liquid, tablet and capsule medicinal products, successfully completing the second phase of the company's business expansion plans.

  • December 2015

    Partnering with Australia

    The Company entered into a legally binding Cooperation Agreement with Rick Carson Partners (Rick Carson) to conduct feasibility studies and determine potential raw suppliers and cooperative partners in Australia.

Our brand is long-standing, highly recognised & respected in the pharmaceutical industry in China


Haixi China's business model is a vertically integrated model. An illustrative diagram is set out below:

Read more


Haixi China produces its own pharmaceutical products. The diagram below illustrates Haixi China's general production process.

Quality control systems

Haixi China has developed and implemented a uniform code of production, which entails strict management protocols and detailed operating procedures which are compliant with GMP production standards. The key areas within the uniform code of production are set out below:

  • Supervision and management of product quality: The QM Department undertakes product testing, auditing and on-site supervision throughout the entire product production process. This process ensures that Haixi China's products are consistently produced at the highest quality and standard for its customers
  • Factory site management: Key areas that the QM Department focuses on include factory temperature, safety of machinery, and storage of raw materials.
  • Inspection and use of raw materials: All raw material sourced from third parties undergo a thorough inspection process before they are accepted and stored. After the initial quality inspection stage, regular inspections are carried out to ensure that quality levels are maintained.
  • Packaging and storage policy: All materials used for packaging undergo a thorough inspection process prior to being accepted by Haixi China. All accepted packaging goods adhere to a high level of hygiene standards and must be free of any harmful or poisonous substances. All packaged goods will undergo a final round of inspections before they are delivered to minimise ensure that they are of the highest standards.
  • Internal review and record keeping: Quality control targets are set and used to monitor all production procedures and quality consistency.

Distribution and Sales

Haixi China sells its products in wholesale quantities to pharmaceutical agencies and intermediaries in order to reduce sales costs and allow for distribution to a wide range of end users. This allows the Group's products to be distributed to a number of provinces in China, including Hubei, Hunan, Jiangxi, Guangdong, Tianjin, Yunnan, Liaoning and Anhui.

Research and Development

Haixi China is committed to developing and continuously improving the quality of its pharmaceutical products and the efficiency of its production processes

To do this, Haixi China has employed 4 licensed pharmacists and 1 assistant engineer to lead its R&D team. It has also built meaningful relationships with other companies, institutions and universities, which are well-recognised for their research work in the pharmaceutical industry, to collaboratively develop and improve its pharmaceutical and medicinal products.

The below table outlines recent R&D projects that Haixi China has undertaken.

Product and project scopePartnerStatusDescription
Anoectochilus Lotus Product SeriesNoneOngoingHaixi China is currently developing a new medicinal product which uses raw and natural material extracts from Anoectochilus Lotus. This will include oral liquid, tablet and capsule products. Haixi China has already begun the testing and sampling of the Anoectochilus Lotus product series and, to date, has applied for the Production Approval for this product. If obtained, it will be the only company in China holding Production Approvals for these products.
Mupirocin and ibuprofen creamFuzhou Chang Fu Xing New Drug Development Co., LtdOngoingIn 2016, Haixi China entered into an agreement with Fuzhou Chang Fu Xing Drug Development Co., Ltd to collaboratively develop a mupirocin and ibuprofen cream.
Terbinafine hydrochloride creamHainan Guodong Pharmaceutical Research Institute Co., Ltd

Xi’an Jiaotong University, School of Pharmacy
Completed (2008)In 2005, Haixi China collaborated with Hainan Guodong Pharmaceutical Research Institute Co., Ltd and Xi’an Jiatong University, School of Pharmacy, to produce a terbinafine hydrochloride cream. This received SFDA approval in 2008 and was successfully added to Haixi China’s product range.
Compound camphor creamJinan Zerui Technology Co., Ltd

Shandong New Drug Evaluation Centre
Completed (2006)In 2004, Haixi China collaborated with Jinan Zerui Technology Co., Ltd and Shandong New Drug Evaluation Centre to develop a compound camphor cream. This received SFDA approval in 2006 and was successfully added to Haixi China’s product range.

Certificates & Awards

Haixi China is recognised by the Chinese Government and has received new national Goods Manufacturing Practices Certification (GMP Certification) issued by the State Food and Drug Administration (SFDA). Haixi China also holds SFDA approvals for the production (Production Approval) of 35 types of medicinal products. This includes an exclusive Production Approval for Chinese herbal anemone, allowing Haixi China to be the only authorised producer of this product in China to date.

Pharmaceutical Productions Permits

Certificate of GMP for Pharmaceutical Products

At Listing, the Board will comprise five members, consisting of 3 Executive Directors and 2 Independent, Non-Executive Directors. The following table provides information regarding the Directors and the management team, including their positions and expertise.